Moreover, TP53 mutation was shown to be associated with poorer response and poorer overall survival to cytotoxic T-lymphocyte antigen-4 (CTLA-4) blockade immunotherapy in metastatic melanoma due to impaired cytotoxic T-cell-induced apoptosis of tumor cells [61]. This evidence concerns the gene TP53 and neoplasm.